View More Recent Stories

Feb 26, 2025 03:55PM TD Cowen Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL), PT $390
Feb 26, 2025 03:52PM Madrigal Pharmaceuticals (MDGL) PT Raised to $469 at Citi
Feb 26, 2025 07:05AM Madrigal Pharma (MDGL) Tops Q4 EPS by $1.77, Beats on Revenue
Feb 3, 2025 04:43AM JMP Securities Biotechnology Overview
Jan 30, 2025 04:56PM Clear Street Starts Madrigal Pharmaceuticals (MDGL) at Buy, 'bullish view on Rezdiffra’s launch and its revenue-generating potential'
Jan 16, 2025 05:08AM Goldman Sachs Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)
Jan 13, 2025 11:04AM Madrigal Pharmaceuticals (MDGL) PT Raised to $392 at Evercore ISI
Jan 13, 2025 06:45AM Madrigal Pharma (MDGL) Reports Prelim Q4
Nov 20, 2024 12:41PM Madrigal Pharmaceuticals (MDGL) PT Raised to $400 at Oppenheimer
Nov 20, 2024 07:46AM TD Cowen Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)
Nov 1, 2024 08:22AM Madrigal Pharma (MDGL) Falls 9.3% Following Data from Novo Nordisk (NVO)
Oct 31, 2024 07:05AM Madrigal Pharma (MDGL) Tops Q3 EPS by $1.84, Beats on Revenue
Oct 21, 2024 08:04AM Madrigal Pharma (MDGL) Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis
Oct 8, 2024 07:16AM Piper Sandler Reiterates Overweight Rating on Madrigal Pharmaceuticals (MDGL)
Oct 1, 2024 08:06AM Madrigal Pharma (MDGL) Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development
Sep 30, 2024 08:07AM Madrigal Pharma (MDGL)Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra
Sep 7, 2024 08:00PM Here's the list of biotech stocks that have key data catalysts in 2025
Aug 7, 2024 07:07AM Madrigal Pharma (MDGL) Tops Q2 EPS by 38c
Jun 28, 2024 06:00AM Cantor Fitzgerald Starts Madrigal Pharmaceuticals (MDGL) at Neutral
Jun 11, 2024 05:01AM Wolfe Research Starts Madrigal Pharmaceuticals (MDGL) at Outperform
View More Recent Stories